222 related articles for article (PubMed ID: 31921432)
1. Scoring systemic lupus erythematosus (SLE) disease activity with simple, rapid outcome measures.
Thanou A; James JA; Arriens C; Aberle T; Chakravarty E; Rawdon J; Stavrakis S; Merrill JT; Askanase A
Lupus Sci Med; 2019; 6(1):e000365. PubMed ID: 31921432
[TBL] [Abstract][Full Text] [Related]
2. Preliminary test of the LFA rapid evaluation of activity in lupus (LFA-REAL): an efficient outcome measure correlates with validated instruments.
Askanase A; Li X; Pong A; Shum K; Kamp S; Carthen F; Aberle T; Hanrahan L; Daly P; Giles J; Merrill JT
Lupus Sci Med; 2015; 2(1):e000075. PubMed ID: 25861457
[TBL] [Abstract][Full Text] [Related]
3. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the Lupus Foundation of America-Rapid Evaluation of Activity in Lupus to More Complex Disease Activity Instruments As Evaluated by Clinical Investigators or Real-World Clinicians.
Askanase AD; Nguyen SC; Costenbader K; Lim SS; Kamen D; Aranow C; Grossman J; Kapoor TM; Baker-Frost D; Aberle T; Thanou-Stavraki A; Hanrahan LM; Kim M; Merrill JT
Arthritis Care Res (Hoboken); 2018 Jul; 70(7):1058-1063. PubMed ID: 28992399
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of RNase therapy in systemic lupus erythematosus: a randomised phase 2a clinical trial of RSLV-132.
Burge DJ; Werth VP; Boackle SA; Posada J
Lupus Sci Med; 2024 Feb; 11(1):. PubMed ID: 38325898
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Responsiveness of British Isles Lupus Assessment Group 2004 Index, Systemic Lupus Erythematosus Disease Activity Index 2000, and British Isles Lupus Assessment Group 2004 Systems Tally.
Yee CS; Gordon C; Isenberg DA; Griffiths B; Teh LS; Bruce IN; Ahmad Y; Rahman A; Prabu A; Akil M; McHugh N; Edwards CJ; D'Cruz D; Khamashta MA; Farewell VT
Arthritis Care Res (Hoboken); 2022 Oct; 74(10):1623-1630. PubMed ID: 33787088
[TBL] [Abstract][Full Text] [Related]
7. Performance of systemic lupus erythematosus responder index for detecting clinician-rated responders in patients with active systemic lupus erythematosus.
Leosuthamas P; Narongroeknawin P; Chaiamnuay S; Asavatanabodee P; Pakchotanon R
Int J Rheum Dis; 2023 Apr; 26(4):667-672. PubMed ID: 36802112
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): prespecified analysis of the phase III ustekinumab trial in patients with SLE.
Askanase AD; Tang W; Zuraw Q; Gordon R; Brotherton B; Merrill JT
Lupus Sci Med; 2023 Apr; 10(1):. PubMed ID: 37012059
[TBL] [Abstract][Full Text] [Related]
9. How should lupus flares be measured? Deconstruction of the safety of estrogen in lupus erythematosus national assessment-systemic lupus erythematosus disease activity index flare index.
Thanou A; Chakravarty E; James JA; Merrill JT
Rheumatology (Oxford); 2014 Dec; 53(12):2175-81. PubMed ID: 24729400
[TBL] [Abstract][Full Text] [Related]
10. [Feasibility of SLEDAI-2000 and BILAG-2004 scoring systems for assessing renal disease activity in children with lupus nephritis].
Zhou JQ; Jiang H
Zhongguo Dang Dai Er Ke Za Zhi; 2012 Oct; 14(10):775-9. PubMed ID: 23092572
[TBL] [Abstract][Full Text] [Related]
11. Changes in quality of life in relation to disease activity in systemic lupus erythematosus: post-hoc analysis of the BLISS-52 Trial.
Jolly M; Annapureddy N; Arnaud L; Devilliers H
Lupus; 2019 Dec; 28(14):1628-1639. PubMed ID: 31674267
[TBL] [Abstract][Full Text] [Related]
12. Associations of the Levels of C4d-bearing Reticulocytes and High-avidity Anti-dsDNA Antibodies with Disease Activity in Systemic Lupus Erythematosus.
Mora C; Medina-Rosas J; Santos AM; Jaimes DA; Arbeláez AM; Romero C; Cortes A; Londono J
J Rheumatol; 2016 Sep; 43(9):1657-64. PubMed ID: 27134246
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): data from the Peruvian Almenara Lupus Cohort.
Ugarte-Gil MF; Gamboa-Cardenas RV; Reátegui-Sokolova C; Pimentel-Quiroz VR; Zeña-Huancas P; Elera-Fitzcarrald C; Garcia-Hirsh S; Gil L; Pastor-Asurza CA; Rodriguez-Bellido Z; Merrill J; Askanase AD; Alarcon G; Perich-Campos RA
Lupus Sci Med; 2020 Oct; 7(1):. PubMed ID: 33046557
[TBL] [Abstract][Full Text] [Related]
14. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials.
Manzi S; Sánchez-Guerrero J; Merrill JT; Furie R; Gladman D; Navarra SV; Ginzler EM; D'Cruz DP; Doria A; Cooper S; Zhong ZJ; Hough D; Freimuth W; Petri MA;
Ann Rheum Dis; 2012 Nov; 71(11):1833-8. PubMed ID: 22550315
[TBL] [Abstract][Full Text] [Related]
15. Which outcome measures in SLE clinical trials best reflect medical judgment?
Thanou A; Chakravarty E; James JA; Merrill JT
Lupus Sci Med; 2014; 1(1):e000005. PubMed ID: 25396057
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus.
Ward MM; Marx AS; Barry NN
J Rheumatol; 2000 Mar; 27(3):664-70. PubMed ID: 10743805
[TBL] [Abstract][Full Text] [Related]
17. Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial.
Tanaka Y; Bass D; Chu M; Egginton S; Ji B; Roth D
Mod Rheumatol; 2020 Mar; 30(2):313-320. PubMed ID: 31199180
[No Abstract] [Full Text] [Related]
18. Novel evidence-based systemic lupus erythematosus responder index.
Furie RA; Petri MA; Wallace DJ; Ginzler EM; Merrill JT; Stohl W; Chatham WW; Strand V; Weinstein A; Chevrier MR; Zhong ZJ; Freimuth WW
Arthritis Rheum; 2009 Sep; 61(9):1143-51. PubMed ID: 19714615
[TBL] [Abstract][Full Text] [Related]
19. Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus.
Furie RA; Bruce IN; Dörner T; Leon MG; Leszczyński P; Urowitz M; Haier B; Jimenez T; Brittain C; Liu J; Barbey C; Stach C
Rheumatology (Oxford); 2021 Nov; 60(11):5397-5407. PubMed ID: 33956056
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials.
Morand EF; Furie RA; Bruce IN; Vital EM; Dall'Era M; Maho E; Pineda L; Tummala R
Lancet Rheumatol; 2022 Apr; 4(4):e282-e292. PubMed ID: 38288923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
